Literature DB >> 20193640

Behavioral and cognitive effects of anti-epileptic drugs.

Andrea Eugenio Cavanna1, Fizzah Ali, Hugh Edward Rickards, Dougall McCorry.   

Abstract

Anti-epileptic drugs (AEDs) have a variety of mechanisms of action which are reflected through different anticonvulsant activities and behavioral effects. Two categories of AEDs are considered based on psychotropic profile. The first group is characterized by potentiation of gamma-aminobutyric acid (GABA) inhibitory neurotransmission, and comprises of agents such as vigabatrin, tiagabine, and gabapentin. These agents are noted to have sedating effects ranging from cognitive slowing to anti-manic effects. On the other hand, the second group is typified by attenuation of glutamate excitatory neurotransmission and has activating effects including anxiogenic and antidepressant actions. Lamotrigine and felbamate feature in this latter group. Mechanisms of action, chief clinical indications, as well as behavioral profile including comment on chief cognitive effects of the newer AEDs are reviewed in accordance with this dual categorization. In clinical practice, assessment of an individual patient alongside consideration of AED behavioral profile primes for appropriate prescription according to patient mood profile, also permitting exposure of AED-induced behavioral disturbance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193640

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  14 in total

1.  HIV gp120-induced neuroinflammation potentiates NMDA receptors to overcome basal suppression of inhibitory synapses by p38 MAPK.

Authors:  Xinwen Zhang; Matthew V Green; Stanley A Thayer
Journal:  J Neurochem       Date:  2019-01-18       Impact factor: 5.372

2.  Selection of antiepileptic drugs in older people.

Authors:  Batool F Kirmani; Diana Mungall Robinson; Adeline Kikam; Ekokobe Fonkem; Daniel Cruz
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.972

3.  Neurobehavioral effects of vigabatrin and its ability to induce DNA damage in brain cells after acute treatment in rats.

Authors:  Karen Sousa; Natalia Decker; Thienne Rocha Pires; Débora Kuck Mausolff Papke; Vanessa Rodrigues Coelho; Pricila Pflüger; Patrícia Pereira; Jaqueline Nascimento Picada
Journal:  Psychopharmacology (Berl)       Date:  2016-09-27       Impact factor: 4.530

Review 4.  Women with epilepsy: clinically relevant issues.

Authors:  S Bangar; Abhishek Shastri; Hany El-Sayeh; Andrea E Cavanna
Journal:  Funct Neurol       Date:  2016 Jul-Sep

5.  Decision making in juvenile myoclonic epilepsy.

Authors:  Laura Zamarian; Julia Höfler; Giorgi Kuchukhidze; Margarete Delazer; Elisabeth Bonatti; Georg Kemmler; Eugen Trinka
Journal:  J Neurol       Date:  2012-10-27       Impact factor: 4.849

6.  Pharmacotherapeutic and Non-Pharmacological Options for Refractory and Difficult-to-Treat Seizures.

Authors:  James W Mitchell; Stefano Seri; Andrea E Cavanna
Journal:  J Cent Nerv Syst Dis       Date:  2012-06-19

7.  Executive functions in chronic mesial temporal lobe epilepsy.

Authors:  Laura Zamarian; Eugen Trinka; Elisabeth Bonatti; Giorgi Kuchukhidze; Thomas Bodner; Thomas Benke; Florian Koppelstaetter; Margarete Delazer
Journal:  Epilepsy Res Treat       Date:  2011-03-06

8.  Risk of psychiatric disorders following trigeminal neuralgia: a nationwide population-based retrospective cohort study.

Authors:  Tung-Han Wu; Li-Yu Hu; Ti Lu; Pan-Ming Chen; Hon-Jhe Chen; Cheng-Che Shen; Chun-Hsien Wen
Journal:  J Headache Pain       Date:  2015-07-15       Impact factor: 7.277

9.  The psychoactive effects of psychiatric medication: the elephant in the room.

Authors:  Joanna Moncrieff; David Cohen; Sally Porter
Journal:  J Psychoactive Drugs       Date:  2013 Nov-Dec

Review 10.  Clinical utility of implantable neurostimulation devices as adjunctive treatment of uncontrolled seizures.

Authors:  Joanna H Cox; Stefano Seri; Andrea E Cavanna
Journal:  Neuropsychiatr Dis Treat       Date:  2014-11-14       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.